1. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. (January 2022) Authors: Rubin, David T; Dotan, Iris; DuVall, Aaron; Bouhnik, Yoram; Radford-Smith, Graham; Higgins, Peter D R; Mishkin, Daniel S; Arrisi, Pablo; Scalori, Astrid; Oh, Young S; Tole, Swati; Chai, Akiko; Chamberlain-James, Kirsten; Lacey, Stuart; McBride, Jacqueline; Panés, Julian; Rustem, Abdulkhakov; Nora... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 1(2022) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Screening for nutrition risk in adults outpatients with inflammatory bowel disease: Results from a multicenter study in Greece and the United Kingdom. (April 2018) Authors: Karayiannis, Dimitrios; Baschali, Aristea; Sarantidou, Magdalini; Alberti, Avra; Mantzaris, Gerassimos; Gerasimidis, Konstantinos; Partha Sarathy, Prasanna; Gaya, Daniel; Lomer, Miranda; Cahill, Orla; Dimitrios, Christodoulou; Konstantinos, Katsanos Journal: Clinical nutrition ESPEN Issue: Volume 24(2018) Page Start: 181 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗